What You Should Know About Perimenopause and Menopause Hormone Therapy

If you have brought up hormone therapy with a physician in the past twenty years, there is a good chance you were told it causes breast cancer, or that you should take the lowest dose for the shortest time possible, or simply that you would be better off riding it out.

That advice traces back to a single trial and to how its results were announced. It is worth understanding, because a lot of women suffered unnecessarily on the strength of this study and the way it was rolled out.

What the Women's Health Initiative actually studied

The WHI was a large trial, and it was stopped early in 2002 when the data showed an increase in breast cancer among women taking estrogen with a progestin. Not just any estrogen and progestin: the trial used a synthetic progestin, medroxyprogesterone acetate, paired with estrogen extracted from horse urine. The finding was announced at a press conference before the data were fully published and peer reviewed. The number they announced was a 26 percent increase in breast cancer risk.

That number deserves three footnotes it never got. First, it sat at the very edge of statistical significance. Statistical significance is the test of whether a finding is likely real or likely chance, and the convention is a 95 percent confidence interval that excludes 1.0. The breast cancer interval ran from 1.00 to 1.59, touching the line exactly. A result that borderline would normally be reported with caution. This one got a press conference.

Second, 26 percent is a relative risk, and relative risk without absolute risk is close to meaningless. In absolute terms the increase worked out to roughly 8 additional cases per 10,000 women per year. That is 0.08 percent. The distinction between those two numbers never made it into the public conversation, and a small numerical difference was received as an imminent threat.

Third, the comparison group hid a problem. About a quarter of the women in the trial had taken hormones earlier in life, and the prior users assigned to placebo went on to have fewer breast cancers than the national average. Comparing against an unusually healthy group inflates the apparent risk of whatever you compare to it. Among the women who had never taken hormones before, the majority of the trial, the difference between the groups was minimal and could not be distinguished from chance.

Here is what the press conference did not lead with: the women in the trial's other arm, who took the horse estrogen alone without the synthetic progestin, went on to show a decreased risk of breast cancer. The alarm was rung over one combination of two specific drugs, and it landed on every hormone, every route and every woman.

The damage was immediate. Within a single year, prescriptions for the exact drug studied fell by two thirds. Millions of women stopped overnight.

Two problems with applying it to you

The first is who was studied. The average woman in the WHI was about 63 years old, and many were ten to fifteen years past menopause, with vascular changes already established and a higher baseline cardiovascular risk. That is not the same person as a symptomatic 51 year old considering hormone therapy near the onset of menopause. Applying conclusions from the first group to the second is a mismatch between the population studied and the population treated.

The second is what was studied. The WHI used oral conjugated equine estrogens (that is horse estrogen, obtained from horse urine) with medroxyprogesterone acetate (a synthetic progestin, not bioidentical progesterone). Those are not what most of us prescribe now. Oral estrogen passes through the liver first, which raises clotting factors and inflammatory markers. Transdermal estradiol, delivered through the skin, largely avoids that. Micronized progesterone behaves differently from the synthetic progestin used in the trial. The risks found in the WHI cannot be assumed to transfer to different drugs given by a different route.

There is one more finding that got almost no attention. Women who took estrogen alone, without a progestin, showed no increase in breast cancer at all. By the study's own math, they showed a 23 percent decrease. Among the younger women there was also a reduction in all cause mortality. Those results directly contradict the story most people remember.

What we understand now

Age at initiation matters. Time since menopause matters. Formulation matters. Route matters. None of that was in the original headline.

Started near the onset of menopause, using bioidentical estradiol delivered through the skin with bioidentical progesterone, the balance of benefit and risk is favorable for most women. Data presented in recent years suggest that starting during perimenopause, rather than waiting, carries a better risk profile still, with reductions in cardiovascular events, UTIs and fractures.

None of this means hormone therapy is right for everyone or free of risk. There are real contraindications, and a woman with a history of breast cancer, unexplained bleeding, or certain clotting disorders needs a careful individual conversation rather than a protocol. What it means is that the reflexive no that many women received was not supported by the evidence it claimed to rest on.

Starting in perimenopause

Plenty of women are told to wait. Come back when your periods have stopped for a year and then we will talk about hormones. That advice is common and I think it is usually wrong.

Perimenopause is where most symptoms begin, and it can run for several years before that twelve month mark ever arrives. Waiting means spending those years symptomatic for no particular reason, and the evidence on timing does not support the delay.

There are real differences in how perimenopause is treated, though, and they are worth knowing.

Progesterone often falls before estrogen does, because ovulation becomes inconsistent and progesterone is produced after ovulation. So the first useful treatment is sometimes progesterone on its own, particularly when the main complaints are insomnia, anxiety and worsening premenstrual symptoms.

Estrogen in perimenopause is also a different problem from estrogen after menopause. Levels are swinging rather than simply low, so the goal is smoothing out the volatility rather than replacing a deficit that has settled in.

Testosterone belongs in this conversation too. Women make it, and in a young healthy woman it is the most prevalent sex hormone she has. Restoring it can help desire, energy, mood, muscle and clarity of thought, and for many women it is the missing piece after estrogen and progesterone are in place.

And you can still get pregnant. Fertility declines through perimenopause but it does not end until it ends, and hormone therapy is not contraception. If pregnancy would be unwelcome, that belongs in the plan rather than as an afterthought.

The practical version is that your symptoms and your reproductive stage should drive this conversation, not a date on a calendar.

What is actually at stake

The conversation about menopause tends to get framed as quality of life, which makes it sound optional. It is more than that.

Estrogen deficiency accelerates bone loss, and it starts earlier than most women are told: the fastest decline begins in the year or two before the final period, and the spine can lose roughly ten percent of its density across the menopause transition. Muscle mass and strength decline, which drives frailty later. Body composition shifts toward visceral fat, insulin sensitivity worsens, and cardiometabolic risk climbs. Genitourinary tissue thins, which produces vaginal dryness, painful sex, urinary urgency, and recurrent urinary tract infections that get progressively worse if nothing is done.

Started early, the numbers run the other way. Hormone therapy cut hip fractures by about a third in the WHI itself. In the one randomized trial that started women near menopause and followed them for a decade, the combined risk of death, heart attack and heart failure fell by about half. And estrogen lowers the risk of the recurrent urinary tract infections that estrogen deficiency invites.

Women now spend thirty to forty percent of their lives after menopause. The cumulative cost of leaving that untreated is not trivial, and it is not only about how you feel this month.

What I would want you to take from this

Menopause is a normal part of life, not a disease. Suffering through it is not a requirement, and it is not evidence of toughness.

If you are symptomatic, the question worth asking your physician is not whether hormone therapy is safe in the abstract. It is whether it is reasonable for you, at your age, at this point in perimenopause or menopause, given your history, using a modern formulation and route. That is a real conversation with a real answer, and it looks different for different women.

The lesson of the WHI is not that hormone therapy is dangerous. It is that oversimplified interpretation of complicated data can distort medical practice for twenty years.